Inotiv Past Earnings Performance
Past criteria checks 0/6
Inotiv's earnings have been declining at an average annual rate of -50.2%, while the Life Sciences industry saw earnings growing at 14.1% annually. Revenues have been growing at an average rate of 49.9% per year.
Key information
-50.2%
Earnings growth rate
-46.5%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 49.9% |
| Return on equity | -54.2% |
| Net Margin | -19.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Inotiv, Inc.'s (NASDAQ:NOTV) 57% Dip In Price Shows Sentiment Is Matching Revenues
Apr 26
Inotiv (NASDAQ:NOTV) Takes On Some Risk With Its Use Of Debt
Mar 19Inotiv, Inc.'s (NASDAQ:NOTV) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Feb 13Inotiv, Inc. (NASDAQ:NOTV) Stock Rockets 61% But Many Are Still Ignoring The Company
Dec 18Earnings Release: Here's Why Analysts Cut Their Inotiv, Inc. (NASDAQ:NOTV) Price Target To US$12.81
Dec 13Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Nov 21Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Aug 14Is Inotiv (NASDAQ:NOTV) Using Debt In A Risky Way?
May 09Inotiv adds 16% on settlement with U.S. over Virginia facility
Jul 18Inotiv completes acquisition of bioanalytical company Protypia for ~$11M
Jul 07Headwaters Capital - Inotiv: Transformation Into A Critical Full-Service Contract Research Organization
May 25Inotiv: Leading Mid-Market CRO Ups Its Game
Feb 07Revenue & Expenses Breakdown
How Inotiv makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 501 | -99 | 103 | 0 |
| 31 Mar 24 | 553 | -71 | 112 | 0 |
| 31 Dec 23 | 585 | -33 | 120 | 0 |
| 30 Sep 23 | 572 | -105 | 127 | 0 |
| 30 Jun 23 | 582 | -340 | 127 | 0 |
| 31 Mar 23 | 597 | -345 | 123 | 0 |
| 31 Dec 22 | 586 | -341 | 116 | 0 |
| 30 Sep 22 | 548 | -337 | 99 | 0 |
| 30 Jun 22 | 427 | -83 | 74 | 0 |
| 31 Mar 22 | 277 | -77 | 56 | 0 |
| 31 Dec 21 | 156 | -72 | 36 | 0 |
| 30 Sep 21 | 90 | 11 | 26 | 0 |
| 30 Jun 21 | 75 | 0 | 26 | 0 |
| 31 Mar 21 | 68 | -4 | 23 | 0 |
| 31 Dec 20 | 65 | -4 | 22 | 0 |
| 30 Sep 20 | 60 | -5 | 21 | 1 |
| 30 Jun 20 | 59 | -3 | 20 | 1 |
| 31 Mar 20 | 55 | -2 | 18 | 1 |
| 31 Dec 19 | 48 | -2 | 16 | 1 |
| 30 Sep 19 | 44 | -1 | 14 | 1 |
| 30 Jun 19 | 38 | -1 | 11 | 1 |
| 31 Mar 19 | 33 | -1 | 9 | 1 |
| 31 Dec 18 | 30 | 0 | 8 | 1 |
| 30 Sep 18 | 26 | 0 | 7 | 1 |
| 30 Jun 18 | 23 | 0 | 6 | 1 |
| 31 Mar 18 | 23 | 1 | 6 | 1 |
| 31 Dec 17 | 23 | 1 | 6 | 1 |
| 30 Sep 17 | 24 | 1 | 6 | 0 |
| 30 Jun 17 | 24 | -1 | 6 | 0 |
| 31 Mar 17 | 23 | -2 | 6 | 0 |
| 31 Dec 16 | 22 | -3 | 6 | 0 |
| 30 Sep 16 | 20 | -3 | 6 | 0 |
| 30 Jun 16 | 20 | -2 | 6 | 1 |
| 31 Mar 16 | 21 | 0 | 6 | 1 |
| 31 Dec 15 | 22 | 0 | 6 | 1 |
| 30 Sep 15 | 23 | 1 | 6 | 1 |
| 30 Jun 15 | 24 | 1 | 6 | 1 |
| 31 Mar 15 | 24 | 0 | 7 | 1 |
| 31 Dec 14 | 24 | 0 | 7 | 1 |
| 30 Sep 14 | 25 | -1 | 7 | 1 |
| 30 Jun 14 | 24 | 0 | 7 | 1 |
| 31 Mar 14 | 23 | 0 | 6 | 1 |
| 31 Dec 13 | 22 | 0 | 6 | 1 |
| 30 Sep 13 | 22 | 1 | 6 | 0 |
Quality Earnings: NOTV is currently unprofitable.
Growing Profit Margin: NOTV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NOTV is unprofitable, and losses have increased over the past 5 years at a rate of 50.2% per year.
Accelerating Growth: Unable to compare NOTV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NOTV is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-10.8%).
Return on Equity
High ROE: NOTV has a negative Return on Equity (-54.2%), as it is currently unprofitable.